Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. - Wikidata - awgldk - TriplyDB

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.

http://www.wikidata.org/entity/Q35504164

about

Management of endocrine disease: Secondary osteoporosis: pathophysiology and management Advances in the evaluation and management of esophageal disease of systemic sclerosis.Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study.Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin.The relationship between long-term proton pump inhibitor therapy and skeletal frailty.A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety.Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey.Proton pump inhibitors use and change in bone mineral density.Risk of fracture in adults on renal replacement therapy: a Danish national cohort study.Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with three-group matching weights.Letter: proton pump inhibitor use and fracture risk.Adverse bone effects of medications used to treat non-skeletal disorders.Effects of the Histamine 1 Receptor Antagonist Cetirizine on the Osteoporotic Phenotype in H(+) /K(+) ATPase Beta Subunit KO Mice.Impaired skeletal health in patients with chronic atrophic gastritis.Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors Proton pump inhibitors and fracture: they impair bone quality and increase fall risk?Calcium, proton pump inhibitors, and fracture risk Bone Health During the Menopause Transition and Beyond Quantifying Candidacy for Deprescribing of Proton Pump Inhibitors among Long-Term Care Residents Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis

P2860

Q26998249-90A58962-5F69-4D7E-9148-3EE97BBF71FF Q34666835-7F34CFAB-1A30-4C9B-ABA9-C1D9C31530A5 Q36743913-C38C1F3C-12DC-4E1D-B2AB-C5810598A948 Q37330132-0B3F4BE3-40EE-4A49-9994-610BE4CE2BA2 Q37388809-64E9C53F-6EED-4306-A16E-5EC35AB6BB5B Q38724116-00B205C1-AE55-407F-8AD8-695D25544BAE Q39109115-B7C8FF1A-FFD2-4081-9BDE-AAE9F39C74DE Q39724310-FD126603-AD42-4BFB-93CF-52E19A201889 Q39758072-18E88C19-8B2D-4C76-B473-29F84C047446 Q40010387-FC5F4BAC-4C2B-463D-B84B-E69E9024C019 Q47579387-C30A0D75-F3CC-4C84-9026-CD3F763B38BB Q48288782-C994BA4F-14C4-4F73-8E88-5039FB450B6B Q48332195-778106AE-C8D7-409A-ADDD-1FC197C6FE85 Q50931979-9B96DA58-9785-4560-AD60-A4C779FF469F Q50933424-99E82E30-59CF-4B31-A885-137023C72495 Q57271829-62F70A5E-E33E-48A4-8F3D-FA1F3F9E8E5F Q57565630-89B980AE-0465-46EA-8415-87CD457479B8 Q57565640-F56D9C24-FC7D-4D3B-B46A-BA0BBE82A75D Q58551796-BA16F2A1-A290-4792-A2A3-AD2B72017FD1 Q58557250-E58C6D06-57F3-41E5-9A43-1058AC10DF76 Q58780145-F6879423-D34C-453D-916E-6802D54D780B

P2860

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.

http://www.wikidata.org/entity/Q35504164

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Bone mineral density changes a ...... agonists: a SWAN cohort study.

@ast

Bone mineral density changes a ...... agonists: a SWAN cohort study.

@en

type

label

Bone mineral density changes a ...... agonists: a SWAN cohort study.

@ast

Bone mineral density changes a ...... agonists: a SWAN cohort study.

@en

prefLabel

Bone mineral density changes a ...... agonists: a SWAN cohort study.

@ast

Bone mineral density changes a ...... agonists: a SWAN cohort study.

@en

P1433

Q35504164-371A0E53-3817-48C8-8DD9-DF0D0CA679A0

P1476

Q35504164-88ED49C3-1568-43DE-A4A6-31FA594E4195

P2093

Q35504164-1A1ACC62-686C-4BAC-86C0-0CB3F68826CE

Q35504164-86754B20-61B4-43D6-BD57-F9E8934A4209

Q35504164-8FCC6333-7A0A-429D-905A-46FAF9E166C7

Q35504164-929857CD-5433-4BD7-9826-D5AD174F6216

Q35504164-A0843420-468A-4AA7-8EF2-54BB06CCB873

Q35504164-D81CCC29-0B5A-4ACF-84EB-670DF6F984F4

Q35504164-FB775A23-295A-47CE-8213-127F5F652B21

P2860

Q35504164-01D38248-087B-43FE-ABDC-1A8A4AAAE408

Q35504164-0425C6C1-9861-4715-B53E-432BE6DF38A0

Q35504164-246ED4E0-8D22-4E9D-85AF-97E66A05FD86

Q35504164-250A9F53-F90B-4856-AB7E-0FFD72D58207

Q35504164-25E0F991-00F9-498A-BB44-CBF1A15FF234

Q35504164-3CFCD7B1-CBF2-44CD-9C5F-C88307766CFA

Q35504164-3FF16C3D-3A61-4795-AD9A-CD45969DD61C

Q35504164-4AF7306F-2B5E-46B4-B799-F6BC92087681

Q35504164-69D5F878-489B-4ECC-A537-FC383B559FBA

Q35504164-6AE92E88-3C1A-44D8-B408-512F33D35B39

P304

Q35504164-B82E4E7A-8F95-4878-ADB2-AA885D63D0FB

P31

Q35504164-B658DA25-5F1A-41E3-A60C-F3DA94353CF9

P356

Q35504164-99A9DC9B-017C-42E6-8E52-3233AD79DBAA

P433

Q35504164-062A74CE-DA16-4EA7-95FF-EA624ED2C04E

P478

Q35504164-CFF93A4D-4DA8-494B-922F-D5B3A66B6ACD

P50

Q35504164-FA130AFE-C110-4826-8553-87FCB2E366AE

P577

Q35504164-3E35D378-40A7-4ECC-883B-2953084F990E

P698

Q35504164-D847A9CE-208B-4C4D-A318-DDB90AE3E28B

P932

Q35504164-B7231B82-843C-49FB-8EFE-8B46B21857E5

P356

P1433

Journal of Bone and Mineral Research

P1476

Bone mineral density changes a ...... tagonists: a SWAN cohort study

@en

P2093

Alyssa Wohlfart

http://www.w3.org/2001/XMLSchema#string

Chih-Chin Liu

http://www.w3.org/2001/XMLSchema#string

Daniel H Solomon

http://www.w3.org/2001/XMLSchema#string

Gail A Greendale

http://www.w3.org/2001/XMLSchema#string

Joel S Finkelstein

http://www.w3.org/2001/XMLSchema#string

Susan J Diem

http://www.w3.org/2001/XMLSchema#string

Yin Juan Lian

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoimmunology: interactions of the bone and immune system

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.

Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.

Clinical practice. Postmenopausal osteoporosis.

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative

Long-term proton pump inhibitor therapy and risk of hip fracture.

Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN).

Bone mineral density changes during the menopause transition in a multiethnic cohort of women.

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

P304

232-239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.2344

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Kristine Ruppert

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25156141

http://www.w3.org/2001/XMLSchema#string

P932

4404624

http://www.w3.org/2001/XMLSchema#string